Amerge

Product manufactured by Glaxosmithkline Llc

Application Nr Approved Date Route Status External Links
NDA020763 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Amerge Is Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults. Limitations Of Use • Use Only If A Clear Diagnosis Of Migraine Has Been Established. If A Patient Has No Response To The First Migraine Attack Treated With Amerge, Reconsider The Diagnosis Of Migraine Before Amerge Is Administered To Treat Any Subsequent Attacks. • Amerge Is Not Indicated For The Prevention Of Migraine Attacks. • Safety And Effectiveness Of Amerge Have Not Been Established For Cluster Headache. Amerge Is A Serotonin (5-Ht 1b/1d ) Receptor Agonist (Triptan) Indicated For The Acute Treatment Of Migraine With Or Without Aura In Adults. ( 1 ) Limitations Of Use • Use Only If A Clear Diagnosis Of Migraine Has Been Established. ( 1 ) • Not Indicated For The Prophylactic Therapy Of Migraine Attacks. ( 1 ) • Not Indicated For The Treatment Of Cluster Headache. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Naratriptan Hydrochloride NARATRIPTAN HYDROCHLORIDE ZINC4076

Comments